Treatment-emergent AEs occurring in at least 15% of patients treated with frontline brentuximab vedotin monotherapy
| . | N = 27 . | ||
|---|---|---|---|
| Event* . | Grade 1/2 n (%) . | Grade 3† n (%) . | Total n (%) . |
| Peripheral sensory neuropathy | 14 (52) | 7 (26) | 21 (78) |
| Fatigue | 12 (44) | 0 | 12 (44) |
| Nausea | 12 (44) | 0 | 12 (44) |
| Peripheral edema | 10 (37) | 0 | 10 (37) |
| Diarrhea | 9 (33) | 0 | 9 (33) |
| Decreased appetite | 8 (30) | 0 | 8 (30) |
| Constipation | 7 (26) | 0 | 7 (26) |
| Alopecia | 5 (19) | 0 | 5 (19) |
| Cough | 5 (19) | 0 | 5 (19) |
| Muscular weakness | 5 (19) | 0 | 5 (19) |
| Pruritus | 5 (19) | 0 | 5 (19) |
| Rash | 3 (11) | 2 (7) | 5 (19) |
| Urinary tract infection | 4 (15) | 1 (4) | 5 (19) |
| Vomiting | 5 (19) | 0 | 5 (19) |
| Deep vein thrombosis | 4 (15) | 0 | 4 (15) |
| Dizziness | 4 (15) | 0 | 4 (15) |
| Maculopapular rash | 3 (11) | 1 (4) | 4 (15) |
| Weight decreased | 4 (15) | 0 | 4 (15) |
| . | N = 27 . | ||
|---|---|---|---|
| Event* . | Grade 1/2 n (%) . | Grade 3† n (%) . | Total n (%) . |
| Peripheral sensory neuropathy | 14 (52) | 7 (26) | 21 (78) |
| Fatigue | 12 (44) | 0 | 12 (44) |
| Nausea | 12 (44) | 0 | 12 (44) |
| Peripheral edema | 10 (37) | 0 | 10 (37) |
| Diarrhea | 9 (33) | 0 | 9 (33) |
| Decreased appetite | 8 (30) | 0 | 8 (30) |
| Constipation | 7 (26) | 0 | 7 (26) |
| Alopecia | 5 (19) | 0 | 5 (19) |
| Cough | 5 (19) | 0 | 5 (19) |
| Muscular weakness | 5 (19) | 0 | 5 (19) |
| Pruritus | 5 (19) | 0 | 5 (19) |
| Rash | 3 (11) | 2 (7) | 5 (19) |
| Urinary tract infection | 4 (15) | 1 (4) | 5 (19) |
| Vomiting | 5 (19) | 0 | 5 (19) |
| Deep vein thrombosis | 4 (15) | 0 | 4 (15) |
| Dizziness | 4 (15) | 0 | 4 (15) |
| Maculopapular rash | 3 (11) | 1 (4) | 4 (15) |
| Weight decreased | 4 (15) | 0 | 4 (15) |